Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-3070 transdermal asenapine versus Sycrest 5 mg in healthy volunteers
NL-OMON36902Active, not recruiting
- Sponsor
- Noven Pharmaceuticals
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Secuado and asenapine in schizophrenia and bipolar disorder (BD), sponsored by Noven Pharmaceuticals. Primary endpoint: Pharmacokinetics and relative bioavailability of asenapine after HP-3070 patch application. Started Sep 2012; status: active, not recruiting.
02
Drugs
Secuadoasenapine
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NL-OMON36902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36902.